# Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease

> **NCT00258011** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 3 (actual)

## Conditions studied

- Mucopolysaccharidosis I
- Hurler Syndrome
- Hurler-Scheie Syndrome
- Scheie Syndrome

## Interventions

- **BIOLOGICAL:** Aldurazyme (Recombinant Human Alpha-L-Iduronidase)

## Key facts

- **NCT ID:** NCT00258011
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2014-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258011, "Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00258011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*